![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Revance’s Daxxify for Moderate-to-Severe Frown Lines
FDA Approves Revance’s Daxxify for Moderate-to-Severe Frown Lines
The FDA has approved Revance Therapeutics’ injection Daxxify (daxibotulinumtoxinA-lanm) for the temporary improvement of moderate-to-severe frown lines in adults.
Revance said Daxxify is the first and only long-acting neuromodulator that demonstrates a median duration of six months and up to nine months for some patients.
Agency approval was based on data from a phase 3 clinical trial, with 74 percent of participants achieving an improvement of two grades or more in glabellar lines at week four.
The company previously received a Complete Response Letter (CRL) for its Biologics License Application in October 2021, due to deficiencies found during an FDA premarket inspection of a Revance manufacturing facility.
Upcoming Events
-
18Jul
-
21Oct